DURECT Corp. (DRRX) announced that its New Drug Application, or NDA, for the investigational product POSIDUR has been accepted by the U.S. FDA. The company said the PDUFA goal date, or the date the FDA expects to complete its review of the NDA, has been confirmed as February 12, 2014.
POSIDUR is a post-operative pain relief depot that utilizes DURECT's SABER technology, and is designed to provide up to three days of pain relief after surgery.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.